This is a preview of subscription content, log in via an institution to check access.
Notes
quality-adjusted life-year
Reference
Njei B, et al. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis. Alimentary Pharmacology and Therapeutics : 19 Sep 2016. Available from: URL: http://dx.doi.org/10.1111/apt.13798
Rights and permissions
About this article
Cite this article
Timing & severity influence value of HCV tx with liver transplantation. PharmacoEcon Outcomes News 763, 32 (2016). https://doi.org/10.1007/s40274-016-3445-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3445-y